Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) PT at $7.17

Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Free Report) has received an average rating of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $7.17.

MRSN has been the subject of a number of analyst reports. Wedbush reaffirmed a “neutral” rating and set a $2.00 target price on shares of Mersana Therapeutics in a report on Tuesday, October 31st. Citigroup raised shares of Mersana Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $1.00 to $5.00 in a report on Monday, December 4th.

Check Out Our Latest Stock Report on Mersana Therapeutics

Insiders Place Their Bets

In other news, CFO Brian Deschuytner sold 9,327 shares of Mersana Therapeutics stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $2.71, for a total value of $25,276.17. Following the completion of the transaction, the chief financial officer now owns 54,511 shares of the company’s stock, valued at approximately $147,724.81. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Mersana Therapeutics news, CFO Brian Deschuytner sold 9,327 shares of Mersana Therapeutics stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $2.71, for a total transaction of $25,276.17. Following the completion of the transaction, the chief financial officer now directly owns 54,511 shares of the company’s stock, valued at $147,724.81. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Anna Protopapas sold 29,399 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $2.71, for a total transaction of $79,671.29. Following the completion of the transaction, the director now owns 125,153 shares in the company, valued at $339,164.63. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,108 shares of company stock valued at $127,663. 12.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Mersana Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Fox Run Management L.L.C. bought a new stake in Mersana Therapeutics during the third quarter worth about $28,000. Victory Capital Management Inc. bought a new position in shares of Mersana Therapeutics in the fourth quarter worth about $30,000. Quantbot Technologies LP bought a new position in shares of Mersana Therapeutics in the first quarter worth about $37,000. Metropolitan Life Insurance Co NY lifted its holdings in shares of Mersana Therapeutics by 36.8% in the fourth quarter. Metropolitan Life Insurance Co NY now owns 6,508 shares of the company’s stock worth $38,000 after acquiring an additional 1,750 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Mersana Therapeutics in the second quarter valued at approximately $38,000.

Mersana Therapeutics Price Performance

MRSN opened at $3.67 on Friday. The company has a fifty day moving average price of $2.53 and a two-hundred day moving average price of $1.79. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.68 and a current ratio of 3.68. Mersana Therapeutics has a 52 week low of $0.80 and a 52 week high of $9.62. The firm has a market capitalization of $442.41 million, a PE ratio of -2.06 and a beta of 1.39.

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) last released its earnings results on Tuesday, November 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). Mersana Therapeutics had a negative return on equity of 264.19% and a negative net margin of 482.47%. The business had revenue of $7.70 million for the quarter, compared to analyst estimates of $9.30 million. During the same period in the prior year, the firm posted ($0.61) EPS. Mersana Therapeutics’s revenue was up 38.1% on a year-over-year basis. As a group, analysts anticipate that Mersana Therapeutics will post -1.49 earnings per share for the current year.

About Mersana Therapeutics

(Get Free Report

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates.

See Also

Analyst Recommendations for Mersana Therapeutics (NASDAQ:MRSN)

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.